EOM Pharmaceutical Holdings Reports Promising Preclinical Results and Provides an Update on EOM613 and EOM147

About this update from Eom Pharmaceutical Holdings Inc.

[{"type":"text","content":"Clinical Trials in Cancer Cachexia, Inflammatory Bowel Disease and Retinal Disorders are Planned","length":96,"tagName":"p"},{"type":"text","content":"MONTVALE, N. J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) an innovative biotechnology company focused on developing transformative treatments for chronic inflammatory conditions and debilitating retinal diseases, today provides an update on its preclinical programs in 2025 and its planned clinical activities in 2026 for its two lead product candidates EOM613 and EOM147.","length":419,"tagName":"p"},{"type":"text","content":"In 2025, the company completed IND-enabling toxicological and dosing preclinical animal studies for EOM613 with favorable results. No adverse drug-related toxic effects were seen with daily subcutaneous injections of EOM613 for 28 consecutive days, including at 13.5 times the highest anticipated dosing levels in humans, indicating a wide margin of tolerability. In addition, no adverse effects were seen in tissue upon histopathological testing. Based on these data, combined with previously reported promising results of our Phase I/IIa 2023 human clinical trial in hospitalized COVID-19 patients with cytokine-driven respiratory inflammation in Brazil, we are planning an initial Phase II exploratory clinical trial in patients with Crohn’s disease.","length":753,"tagName":"p"},{"type":"text","content":"This trial is designed to include 15-20 patients and will be conducted at clinical sites in New Brunswick and Lakewood, NJ, under Principal Investigator Arkady Broder, MD, Director of Gastroenterology at the St. Peter’s Healthcare System. The trial will enroll subjects with moderate to severe Crohn’s disease who have failed or could not tolerate at least one conventional therapy. EOM anticipates initiating the trial in the first quarter 2026 to test for signs of clinical remission and endoscopic remission with EOM613 treatment and to measure biomarkers such as C-reactive protein, calprotectin and pro-inflammatory serum cytokines.","length":637,"tagName":"p"},{"type":"text","content":"In addition, based on these preclinical results, EOM plans to reactivate an Investigational New Drug (IND) application for the treatment of cachectic cancer patients at the FDA’s Office of Oncologic Diseases (OOD) with a view to conducting an...

More updates from Eom Pharmaceutical Holdings Inc.